DGIdb - ROMIDEPSIN Drug Record

ROMIDEPSIN chembl:CHEMBL343448 ApprovedAntineoplastic

Alternate Names:

DEPSIPEPTIDE
ISTODAX
ROMIDEPSIN
FR-901228
FK-228
NSC-630176
CHROMADAX
ANTIBIOTIC FR 901228
ISTODAX®
FR901228
FK228
chemidplus:128517-07-7
chembl:CHEMBL343448
pubchem.compound:5352062
rxcui:877510

Drug Info:

Drug Class	antineoplastic agents
Year of Approval	2009
FDA Approval	Cutaneous T-cell lymphoma, Peripheral T-cell lymphoma
Drug Class	Small molecule inhibitor
FDA Approval	approved
Drug Class	small molecule
Drug Indications	antineoplastic agent

(10 More Sources)

Publications:

VanderMolen et al., 2011, Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma., J. Antibiot.
Yao Y et al., 2015, Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities., J Med Chem
Yu et al., 2002, Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228., J. Natl. Cancer Inst.
Cruickshank et al., 2017, Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin., Leukemia
Khan et al., 2004, Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma., Br. J. Haematol.
Sato et al., 2004, FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells., Int. J. Oncol.
Zhu et al., 2001, Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells., Oncogene
Nguyen et al., 2004, Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells., Clin. Cancer Res.
Weiser et al., Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1., J. Immunother.

ROMIDEPSIN CTAG1B

Interaction Score: 6.71

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11265773

Sources:
NCI
ROMIDEPSIN CDKN2D

Interaction Score: 6.71

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11753657

Sources:
NCI
ROMIDEPSIN HDAC1

Interaction Score: 0.54

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Notes

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
21587264

Sources:
TALC MyCancerGenome TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology TTD
ROMIDEPSIN HDAC6

Interaction Score: 0.53

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name Depsipeptide

Mechanism of Interaction Histone deacetylase inhibitor

PMIDs:
21587264 26331334

Sources:
DTC TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology
ROMIDEPSIN HDAC2

Interaction Score: 0.46

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Notes

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
21587264

Sources:
TALC TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology
ROMIDEPSIN HDAC4

Interaction Score: 0.42

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Histone deacetylase inhibitor

Trial Name Depsipeptide

PMIDs:
21587264

Sources:
MyCancerGenome TdgClinicalTrial ChemblInteractions GuideToPharmacology
ROMIDEPSIN HDAC8

Interaction Score: 0.41

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
None found

Sources:
TALC TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology
ROMIDEPSIN HDAC3

Interaction Score: 0.4

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
TALC TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology
ROMIDEPSIN CDKN1A

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15014036

Sources:
NCI
ROMIDEPSIN HDAC7

Interaction Score: 0.36

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Histone deacetylase inhibitor

Direct Interaction yes

Trial Name Depsipeptide

PMIDs:
None found

Sources:
MyCancerGenome TdgClinicalTrial ChemblInteractions GuideToPharmacology
ROMIDEPSIN HDAC9

Interaction Score: 0.3

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
MyCancerGenome TdgClinicalTrial GuideToPharmacology
ROMIDEPSIN HDAC5

Interaction Score: 0.27

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
TdgClinicalTrial ChemblInteractions GuideToPharmacology
ROMIDEPSIN HDAC11

Interaction Score: 0.22

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Depsipeptide

Novel drug target Established target

Mechanism of Interaction Histone deacetylase inhibitor

PMIDs:
None found

Sources:
TdgClinicalTrial ChemblInteractions
ROMIDEPSIN HDAC10

Interaction Score: 0.19

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Histone deacetylase inhibitor

Direct Interaction yes

Trial Name Depsipeptide

PMIDs:
None found

Sources:
TdgClinicalTrial ChemblInteractions
ROMIDEPSIN BIRC5

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14767553

Sources:
NCI
ROMIDEPSIN MCL1

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15059137

Sources:
NCI
ROMIDEPSIN KMT2A

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell line xenograft

Response Type sensitive

PMIDs:
27443263

Sources:
JAX-CKB
ROMIDEPSIN ERBB2

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11929951

Sources:
NCI
ROMIDEPSIN KRAS

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

PMIDs:
None found

Sources:
JAX-CKB

MyCancerGenome: ROMIDEPSIN
- Version: 20-Jun-2017
Alternate Names:

ISTODAX Trade Name

Drug Info:

Drug Class Small molecule inhibitor

FDA Approval Cutaneous T-cell lymphoma, Peripheral T-cell lymphoma

Publications:
TEND: ROMIDEPSIN
- Version: 01-August-2011
Alternate Names:

ROMIDEPSIN Primary Drug Name

Drug Info:

Year of Approval 2009

Drug Class antineoplastic agents

Publications:
TdgClinicalTrial: ROMIDEPSIN
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class small molecule

FDA Approval approved

Publications:

NCI: FR901228

Version: 14-September-2017

Alternate Names:

C1544 NCI drug code

Drug Info:

Publications:

Yu et al., 2002, Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228., J. Natl. Cancer Inst.

Sato et al., 2004, FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells., Int. J. Oncol.

Weiser et al., Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1., J. Immunother.

NCI: DEPSIPEPTIDE

Version: 14-September-2017

Alternate Names:

C1544 NCI drug code

Drug Info:

Publications:

Yu et al., 2002, Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228., J. Natl. Cancer Inst.

Khan et al., 2004, Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma., Br. J. Haematol.

Nguyen et al., 2004, Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells., Clin. Cancer Res.

DTC: ROMIDEPSIN
- Version: 02-September-2020
Alternate Names:

CHEMBL1213490 ChEMBL Drug ID

Drug Info:

Publications:

Yao Y et al., 2015, Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities., J Med Chem
JAX-CKB: Romidepsin
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Cruickshank et al., 2017, Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin., Leukemia
JAX-CKB: romidepsin
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Cruickshank et al., 2017, Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin., Leukemia
TALC: ROMIDEPSIN
- Version: 12-May-2016
Alternate Names:

ISTODAX Drug Trade Name

ROMIDEPSIN Drug Generic Name

ROMIDEPSIN Primary Drug Name

Drug Info:

Publications:
TTD: Romidepsin
- Version: 2020.06.01
Alternate Names:

D0L7LC TTD Drug ID

Drug Info:

Publications:
GuideToPharmacology: 178103585
- Version: 29-September-2020
Alternate Names:

ROMIDEPSIN GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL343448
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1213490
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
TALC: FK-228
- Version: 12-May-2016
Alternate Names:

Drug Info:

Publications:

Notes
Specific Action of the Ligand	Inhibition
Endogenous Drug?	False

Novel drug target	Established target
Trial Name	Depsipeptide
Mechanism of Interaction	Histone deacetylase inhibitor

Direct Interaction	yes
Mechanism of Interaction	Histone deacetylase inhibitor
Trial Name	Depsipeptide

Direct Interaction?	False
Endogenous Drug?	False
Specific Action of the Ligand	Inhibition

Evidence Type	Actionable
Approval Status	Preclinical - Cell line xenograft
Response Type	sensitive

ISTODAX	Drug Trade Name
ROMIDEPSIN	Drug Generic Name
ROMIDEPSIN	Primary Drug Name

antagonist (inhibitory)
inhibitor (inhibitory)

antagonist (inhibitory)
inhibitor (inhibitory)

ROMIDEPSIN Drug Record

ROMIDEPSIN chembl:CHEMBL343448 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11265773

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11753657

Sources: NCI

Interaction Types & Directionality: antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info: Notes Specific Action of the Ligand Inhibition Endogenous Drug? False

PMIDs: 21587264

Sources: TALC MyCancerGenome TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name Depsipeptide Mechanism of Interaction Histone deacetylase inhibitor

PMIDs: 21587264 26331334

Sources: DTC TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology

Interaction Types & Directionality: antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info: Notes Specific Action of the Ligand Inhibition Endogenous Drug? False

PMIDs: 21587264

Sources: TALC TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Histone deacetylase inhibitor Trial Name Depsipeptide

PMIDs: 21587264

Sources: MyCancerGenome TdgClinicalTrial ChemblInteractions GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Specific Action of the Ligand Inhibition Endogenous Drug? False

PMIDs: None found

Sources: TALC TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? False Endogenous Drug? False Specific Action of the Ligand Inhibition

PMIDs: None found

Sources: TALC TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15014036

Sources: NCI

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Histone deacetylase inhibitor Direct Interaction yes Trial Name Depsipeptide

PMIDs: None found

Sources: MyCancerGenome TdgClinicalTrial ChemblInteractions GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

PMIDs: None found

Sources: MyCancerGenome TdgClinicalTrial GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? False Endogenous Drug? False Specific Action of the Ligand Inhibition

PMIDs: None found

Sources: TdgClinicalTrial ChemblInteractions GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name Depsipeptide Novel drug target Established target Mechanism of Interaction Histone deacetylase inhibitor

PMIDs: None found

Sources: TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Histone deacetylase inhibitor Direct Interaction yes Trial Name Depsipeptide

PMIDs: None found

Sources: TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14767553

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15059137

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Preclinical - Cell line xenograft Response Type sensitive

PMIDs: 27443263

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11929951

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Preclinical Response Type sensitive

PMIDs: None found

Interaction Types & Directionality:

n/a

PMIDs:
11265773

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
11753657

Sources:
NCI

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Notes

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
21587264

Sources:
TALC MyCancerGenome TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name Depsipeptide

Mechanism of Interaction Histone deacetylase inhibitor

PMIDs:
21587264 26331334

Sources:
DTC TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Notes

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
21587264

Sources:
TALC TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Histone deacetylase inhibitor

Trial Name Depsipeptide

PMIDs:
21587264

Sources:
MyCancerGenome TdgClinicalTrial ChemblInteractions GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
None found

Sources:
TALC TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
TALC TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
15014036

Sources:
NCI

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Histone deacetylase inhibitor

Direct Interaction yes

Trial Name Depsipeptide

PMIDs:
None found

Sources:
MyCancerGenome TdgClinicalTrial ChemblInteractions GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
MyCancerGenome TdgClinicalTrial GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
TdgClinicalTrial ChemblInteractions GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Depsipeptide

Novel drug target Established target

Mechanism of Interaction Histone deacetylase inhibitor

PMIDs:
None found

Sources:
TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Histone deacetylase inhibitor

Direct Interaction yes

Trial Name Depsipeptide

PMIDs:
None found

Sources:
TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
14767553

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15059137

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell line xenograft

Response Type sensitive

PMIDs:
27443263

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
11929951

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

PMIDs:
None found

Sources:
JAX-CKB

Alternate Names:

ISTODAX Trade Name

Drug Info:

Drug Class Small molecule inhibitor

FDA Approval Cutaneous T-cell lymphoma, Peripheral T-cell lymphoma

Alternate Names:

ROMIDEPSIN Primary Drug Name

Drug Info:

Year of Approval 2009

Drug Class antineoplastic agents

Drug Info:

Drug Indications antineoplastic agent

Drug Class small molecule

FDA Approval approved

Alternate Names:

C1544 NCI drug code

Alternate Names:

C1544 NCI drug code

Alternate Names:

CHEMBL1213490 ChEMBL Drug ID

Publications:

Yao Y et al., 2015, Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities., J Med Chem

Publications:

Cruickshank et al., 2017, Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin., Leukemia